
Dec 16 (Reuters) - Royalty Pharma PLC RPRX.O:
ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN NUVALENT’S NELADALKIB AND ZIDESAMTINIB FOR UP TO $315 MILLION
ROYALTY PHARMA - ROYALTY DURATION FOR BOTH THERAPIES EXTENDS THROUGH 2041 TO 2042
ROYALTY PHARMA - BUYS LOW-SINGLE DIGIT ROYALTY ON NELADALKIB AND ZIDESAMTINIB